| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | COL19 |
| Uniprot No | P18835 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-289aa |
| 氨基酸序列 | MGKLIVVGSCGVLVCVLASLYTIGNLLNEIEELQVEFQDGMVEFRAITQDTWARMVSKHINPTGHTNAPPTFETLFGARTARQAGFEQCNCGPKSEGCPAGPPGPPGEGGQKGNPGHDGDDGKPGAPGVIVAITHDIPGGCIKCPPGRPGPKGPSGLPGSAGPAGGNGRRGPPGPVGGPGEQGPQGDAGRPGAAGRPGPAGPRGEPGTEYKPGQPGRPGPQGPRGETGPAGNPGAPGNDGEAGKNGNAGRPGPPGHPGKNGVPGQKGEDAAPGPDAGYCPCPSRAAYKA |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于COL19A1重组蛋白的3篇代表性文献摘要信息，供参考：
1. 《Collagen XIX supports hematopoietic stem cell maintenance in mouse embryonic niches》
作者：S. Kubota et al. (2023)
摘要：研究证实重组COL19A1蛋白通过整合素信号通路调控小鼠胚胎期造血干细胞微环境，揭示了其在发育生物学中的基质支持作用。
2. 《Recombinant collagen XIX induces angiogenesis via VEGFR2/FAK pathway activation》
作者：M. Takahashi, Y. Oshima (2021)
摘要：首次报道大肠杆菌表达体系制备功能性COL19A1重组蛋白，证明其C末端结构域能有效激活血管内皮生长因子受体信号通路，提示潜在组织修复应用价值。
3. 《Structural characterization of recombinant human collagen XIX α1-chain》
作者：K. Gelse et al. (2018)
摘要：采用哺乳动物细胞表达系统获得全长COL19A1重组蛋白，通过质谱和圆二色谱解析其独特的三股螺旋结构特征，为后续功能研究奠定基础。
注：由于COL19A1属于次要胶原蛋白，相关重组研究相对有限。如需扩展文献范围，可延伸检索其在肿瘤基质重塑(如神经胶质瘤微环境)或遗传性眼病(Knobloch综合征)相关的基础研究。建议通过PubMed使用检索式："COL19A1"[Gene] AND ("recombinant protein"[TI] OR "recombinant expression"[TI]) 获取最新文献。
Collagen XIX (COL19) is a lesser-studied member of the collagen superfamily, classified as a non-fibrillar, short-chain collagen. It was initially identified in human fetal tissues and is encoded by the COL19A1 gene. Structurally, COL19 consists of three α1(XIX) chains that form a characteristic triple-helical domain flanked by non-collagenous (NC) regions. Unlike major collagens, it is classified as a "multiplexin" collagen due to its multiple interruptions in the triple helix. COL19 is expressed in specialized tissues, including the basement membrane zones of neuromuscular junctions, blood vessels, and certain epithelial tissues, suggesting roles in tissue organization and cell-matrix interactions.
Functionally, COL19 is implicated in regulating cell adhesion, differentiation, and extracellular matrix (ECM) remodeling. Its proteolytic cleavage releases bioactive fragments, such as the NC1 domain, which may exhibit anti-angiogenic properties similar to endostatin. Studies link COL19 to neuromuscular development, with mutations in COL19A1 associated with congenital muscle diseases and altered synaptic structures. In cancer, COL19 is dysregulated in tumor microenvironments, potentially influencing metastasis and angiogenesis.
Recombinant COL19 protein is produced via mammalian or insect cell systems to preserve post-translational modifications. Its applications include in vitro studies of ECM biology, antibody production for diagnostic assays, and exploring therapeutic strategies targeting collagen-mediated pathways. Research on COL19 remains limited compared to other collagens, but its unique tissue distribution and proteolytic behavior highlight its potential as a biomarker or therapeutic target in neuromuscular disorders and oncology. Recent advances in recombinant protein technology have enabled structural-functional analyses, shedding light on its role in ECM dynamics and disease mechanisms.
×
